[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100613901":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":10,"centralContacts":10,"locations":20,"responsibleParty":40,"collaborators":10,"id":42,"slug":10,"hasResults":43,"nctId":44,"briefTitle":45,"officialTitle":46,"acronym":47,"eligibilityCriteria":48,"healthyVolunteers":43,"sex":49,"minAge":50,"maxAge":10,"enrollmentInfo":51,"targetDuration":10,"studyType":54,"phases":10,"briefSummary":55,"conditions":56,"keywords":10,"overallStatus":23,"whyStopped":10,"lastUpdateSubmitDate":58,"lastUpdatePostDateStruct":59,"startDateStruct":62,"completionDateStruct":64,"leadSponsor":66,"locationsCount":67},{"fullName":5,"class":6},"Region Stockholm","OTHER_GOV",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"Patients with Suspected or Known Brain Metastases",null,"Participants undergoing clinically indicated brain MRI with gadolinium contrast who will receive both conventional T1-weighted imaging and the novel gadolinium-weighted MRI sequence during the same scan session. The purpose is to compare lesion detection and conspicuity between the two sequences.",[13],"Diagnostic Test: Novel Gadolinium-Weighted MRI Sequence",[15],{"type":16,"name":17,"description":18,"armGroupLabels":19,"otherNames":10},"DIAGNOSTIC_TEST","Novel Gadolinium-Weighted MRI Sequence","A post-contrast MRI sequence incorporating magnetization transfer (MT) preparation and flow-nulling with motion-sensitized driven equilibrium (MSDE). The sequence is optimized to suppress background tissue and vascular signal while enhancing the visibility of gadolinium-enhancing brain metastases. It is compared to conventional T1-weighted imaging in the same exam session.",[9],[21],{"facility":22,"status":23,"city":24,"state":25,"zip":26,"country":27,"cosmosGeoPoint":28,"geoPoint":33,"contacts":34},"Karolinska University Hospital","RECRUITING","Stockholm","Solna","1171 76","Sweden",{"type":29,"coordinates":30},"Point",[31,32],18.06871,59.32938,{"lat":32,"lon":31},[35],{"name":36,"role":37,"phone":38,"phoneExt":10,"email":39},"Johan Lundberg, Associate professor","CONTACT","+46725802949","johan.h.lundberg@regionstockholm.se",{"type":41,"investigatorFullName":10,"investigatorTitle":10,"investigatorAffiliation":10,"oldNameTitle":10,"oldOrganization":10},"SPONSOR","100613901",false,"NCT07272616","Detection of Brain Metastases Using a Novel Gadolinium-Weighted MRI Sequence: A Prospective Comparison","A Prospective Comparative Study of a Novel Gadolinium-Weighted MRI Sequence Versus Conventional T1-Weighted Imaging for the Detection of Brain Metastases","GDW","Inclusion Criteria:\n\n* Age 18 years or older\n* Scheduled for clinical brain MRI with gadolinium contrast\n* Known or suspected brain metastases\n* Able to provide informed consent\n* Able to lie still for the duration of the MRI examination\n\nExclusion Criteria:\n\n* Contraindications to MRI\n* Known allergy or contraindication to gadolinium-based contrast agents\n* Renal impairment (eGFR \\\u003C 30 mL\u002Fmin\u002F1.73m²)\n* Pregnant or breastfeeding\n* Inability to comply with study procedures","ALL","18 Years",{"count":52,"type":53},100,"ESTIMATED","OBSERVATIONAL","This study will evaluate a new type of MRI sequence designed to improve the visibility of brain metastases after gadolinium contrast injection. The purpose is to determine whether this novel \"gadolinium-weighted\" imaging method can detect more or smaller tumors than standard MRI techniques. Participants will undergo a routine brain MRI with contrast, followed by an additional scan using the new method. The goal is to improve diagnostic accuracy without increasing the contrast dose or scan time.",[57],"Brain Neoplasms","2026-01-29",{"date":60,"type":61},"2026-01-30","ACTUAL",{"date":63,"type":61},"2026-01-28",{"date":65,"type":53},"2027-12-31",{"name":5,"class":6},1]